[ad_1] Novo Nordisk on Friday raised its outlook for its full-year sales and operating profit due to soaring demand for its blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. …
Tag: Novo
Novo Nordisk raises full-year guidance again as US sales of Wegovy, Ozempic fly
[ad_1] [1/2]A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights…
Novo Nordisk stops Ozempic kidney trial after early signs of success
[ad_1] Pens for the diabetes drug Ozempic sit on a production line to be packaged at Danish drugmaker Novo Nordisk’s site in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo…
Novo Nordisk’s Growth Camouflages Weak Spots in Danish Economy
[ad_1] The massive growth of Novo Nordisk A/S is concealing weaknesses in Denmark’s economy, which would have stagnated over the past year and a half without its pharmaceutical industry. Drugmakers…
Novo Nordisk’s Wegovy bonanza looms large in Denmark
[ad_1] COPENHAGEN, Oct 5 (Reuters) – The whirlwind success of weight-loss treatment Wegovy is providing a bonanza not just for its developer, Novo Nordisk (NOVOb.CO), but also for its home…
Novo Nordisk weight-loss drugs like Ozempic have promise
[ad_1] Wegovy, a drug made by Novo Nordisk to treat obesity, was approved by the U.S. FDA in 2021. Michael Siluk—UCG/Universal Images Group/Getty Images It didn’t take much for Novo…
US Patent Office won’t review two Novo Nordisk patents for Wegovy, Ozempic
[ad_1] Flags with the Novo Nordisk logo flutter outside their Danish company’s offices in Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little /File Photo Acquire Licensing Rights WASHINGTON, Oct 2 (Reuters)…
Launches of Novo Nordisk’s weight-loss drug Wegovy
[ad_1] A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights…